查看文章

Chronic lymphocytic leukemia (CLL) is the most common hematologic malignancy among the elderly in the western world, characterized by remarkable clinical and biological heterogeneity, which likely reflects the underlying diverse genomic background. 1 CLL is the prototype of disease in which the concept of precision medicine is applied in the clinical setting, as several disease features are taken into consideration and dictate treatment choice. 2 Among those, the genomic aberrations carried by the clonal population are probably the most established. Indeed, all recent official guidelines regarding the treatment algorithm of CLL propose various management options depending among others on the presence of aberrations in the TP53 gene (deletion of chromosome 17p [del (17p)] or TP53 mutations) as well as the immunogenetic features of the clonotypic B-cell receptor (BcR), namely the segregation into a …